Determinants of persistence with bisphosphonates: A study in women with postmenopausal osteoporosis

Clinical Therapeutics

Volumn 28, Issue 2, 2006, Pages 236-242

  Penning van Beest, Fernie J A ^a   Goettsch, Wim G ^a   Erkens, Joëlle A ^a   Herings, Ron M C ^a,b  

^a PHARMO INSTITUTE FOR DRUG OUTCOMES RESEARCH   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

bisphosphonates; dose regimen; gastrointestinal side effects; osteoporosis; persistence; postmenopausal

Indexed keywords

ALENDRONIC ACID; ANTACID AGENT; ANTIDIARRHEAL AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM CARBONATE; CORTICOSTEROID; ETIDRONIC ACID; GASTROINTESTINAL AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; LAXATIVE; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; RALOXIFENE; RISEDRONIC ACID; BONE DENSITY CONSERVATION AGENT; DRUG DERIVATIVE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DATA BASE; DRUG TREATMENT FAILURE; FEMALE; FRACTURE; GASTROINTESTINAL SYMPTOM; HORMONE SUBSTITUTION; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MENOPAUSAL SYNDROME; MULTIVARIATE ANALYSIS; NETHERLANDS; PHARMACY; POSTMENOPAUSE OSTEOPOROSIS; AGE; CHEMICALLY INDUCED DISORDER; DRUG ADMINISTRATION; FACTUAL DATABASE; GASTROINTESTINAL DISEASE; MIDDLE AGED; PATIENT COMPLIANCE; PRESCRIPTION; STATISTICS;

AGE FACTORS; AGED; ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; DATABASES, FACTUAL; DRUG ADMINISTRATION SCHEDULE; ETIDRONIC ACID; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NETHERLANDS; OSTEOPOROSIS, POSTMENOPAUSAL; PATIENT COMPLIANCE; PRESCRIPTIONS, DRUG;

EID: 33744774092     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2006.01.002     Document Type: Article

References (14)

1. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 285 (2001) 785-795
2. Cummings S., and Melton L. Epidemiology and outcomes of osteoporotic fractures. Lancet 359 (2002) 1761-1767
3. McClung M. Bisphosphonates in osteoporosis: Recent clinical experience. Expert Opin Pharmacother 1 (2000) 225-238
4. for the Alendronate Phase III Osteoporosis Treatment Study Group. Bone H., Hosking D., Devogelaer J., et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350 (2004) 1189-1199
5. McCombs J., Thiebaud P., McLaughlin-Miley C., and Shi J. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48 (2004) 271-287
6. Baker D. Alendronate and risedronate: What you need to know about their upper gastrointestinal tract toxicity. Rev Gastroenterol Disord 2 (2002) 20-33
7. Simon J., Lewiecki E., Smith M., et al. Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: A multicenter, randomized, openlabel, crossover study. Clin Ther. 24 (2002) 1871-1886
8. Kendler D., Kung A., Fuleihan G.-H., et al. Patients with osteoporosis prefer once weekly to once daily dosing with alendronate. Maturitas 48 (2004) 243-251
9. International Classification of Diseases, Ninth Revision, Clinical Modification. 6th ed. (2003), US Dept of Health and Human Services, Centers for Disease Control and Prevention, Centers for Medicare and Medicaid Services, Washington, DC
10. [dissertation]. Herings R. PHARMO: A Record Linkage System for Postmarketing Surveillance of Prescription Drugs in The Netherlands (1993), Utrecht University, Department of Pharmaco-epidemiology and Pharmacotherapy, Utrecht, The Netherlands
11. Catalan V., and LeLorier J. Predictors of long-term persistence on statins in a subsidized clinical population. Value Health 3 (2000) 417-426
12. Graham D. What the gastroenterologist should know about the gastrointestinal safety profiles of bisphosphonates. Dig Dis Sci. 47 (2002) 1665-1678
13. Turbi C., Herrero-Beaumont G., Acebes J., et al. Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: An open-label, prospective, non-randomized, observational study. Clin Ther. 26 (2004) 245-256
14. Segal E., Tamir A., and Ish-Shalom S. Compliance of osteoporotic patients with different treatment regimens. Isr Med Assoc J. 5 (2003) 859-862